Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
US Patent 12012411 Viral replication inhibitors
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Patent
0
Date Filed
November 30, 2021
0
Date of Patent
June 18, 2024
0
Patent Application Number
17538532
0
Patent Citations
US Patent 8884030 Inhibitors of
0
US Patent 8993604 Treatment and prevention of dengue virus infections
0
US Patent 9029376 Small molecule inhibitors for the treatment or prevention of dengue virus infection
0
US Patent 9522923 Selective BACE1 inhibitors
0
US Patent 9944598 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
0
US Patent 10029984 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
0
US Patent 10064870 Sol-gel polymer composites and uses thereof
0
US Patent 10071961 Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
0
US Patent 10206902 Mono- or di-substituted indoles as dengue viral replication inhibitors
0
US Patent 10117850 Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
0
•••
Patent Inventor Names
Wim Smets
0
Mohamed Koukni
0
Dorothée Bardiot
0
Gunter Carlens
0
Michael McNaughton
0
Johan Neyts
0
Arnaud Marchand
0
Kai Dallmeier
0
Suzanne Kaptein
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
12012411
0
Patent Primary Examiner
Shawquia Jackson
0
CPC Code
C07D 487/04
0
Find more entities like US Patent 12012411 Viral replication inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
By using this site, you agree to our
Terms of Service
.
SUBSCRIBE